The U.S. FDA has approved Epsolay® (benzoyl peroxide, cream, 5%), from Sol-Gel Technologies, to treat inflammatory lesions of rosacea in adults.

• Epsolay uses a proprietary microencapsulation technology that slowly release benzoyl peroxide over time. It is the first benzoyl peroxide formulation FDA approved to treat rosacea.
• Under the recommended dosing, a pea-sized amount of Epsolay is applied once daily in a thin layer to each area of the face (forehead, chin, nose, and each cheek). Any unused Epsolay must be discarded 30 days after opening.
• Epsolay has launched at a wholesale acquisition cost (WAC) of $475 per 30g pump.